Net foreign currency transaction and remeasurement losses totaled $0.5 million and $0.4 million, respectively, during the three months ended March 31, 2018 and 2017 and $2.5 million and $1.0 million, respectively, during the six months ended March 31, 2018 and 2017.
As of March 31, 2018, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
The new guidance introduces a new "expected loss" impairment model that applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities and other financial assets.
Based on the preliminary assessment, the Company anticipates that the new guidance will impact the timing of revenue recognition for a portion of its life science revenue which is currently accounted for under the percentage of completion method.
The Company may be required to recognize revenue for a portion of these arrangements at the point in time it satisfies performance obligations by transferring control over promised deliverables to customers in accordance with the contractual terms of each arrangement.
For further information with regard to the Company’s Significant Accounting Policies, please refer to Note 2 "Summary of Significant Accounting Policies" to the Company’s consolidated financial statements included in the 2017 Annual Report on Form 10‑K.
The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the Company’s unaudited Consolidated Balance Sheets.
The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value.
As of March 31, 2018, the aggregate fair value of the marketable securities in an unrealized loss position was $39.7 million and was comprised of U.S. Treasury securities and obligations of U.S. government agencies, U.S. corporate securities, municipal securities and bank certificates of deposits.
Cash equivalents of $51.2 million and less than $0.1 million, respectively, at March 31, 2018 and September 30, 2017 consist of money market funds and are classified within Level 1 of fair value hierarchy because they are valued using quoted market prices in active markets.This section provides an analysis of our financial results for the three and six months ended March 31, 2018 compared to the three and six months ended March 31, 2017.
Over the past several years, we have acquired and developed essential capabilities required to strategically address the sample management needs across multiple end markets within the life sciences industry.
Gross margin was 40.6% for the second quarter of fiscal year 2018 as compared to 38.1% for the second quarter of fiscal year 2017, which resulted in an increase in gross profit of $19.7 million.
Operating expenses were $60.4 million during the second quarter of fiscal year 2018 as compared to $49.7 million during the second quarter of fiscal year 2017, an increase of $10.7 million.
Net income was $67.0 million for the three months ended March 31, 2018 as compared to $14.0 million for the corresponding period of the prior fiscal year.
These increases were partially offset by higher non-operating expenses of $1.9 million compared to the corresponding period of the prior fiscal year, primarily related to interest expense on the term loan and lower net income from equity method investments of $1.4 million.
Results of Operations- Revenue for the six months ended March 31, 2018 increased to $396.6 million, or by 20%, as compared to the corresponding period of the prior fiscal year.
Gross margin was 40.2% for the six months ended March 31, 2018 as compared to 36.9% for the six months ended March 31, 2017, which resulted in an increase in gross profit of $38.0 million.